RESEARCH
Research before it enters your portfolio.
Browse by category or search every fund in the signed snapshot — including the ones you do not own — sort on real returns, shortlist, and compare without leaving the page. Your query stays in the browser.
8,504 funds · figures as of 3 Sep 2026.
A varied 40 to start · pick a category or search
FundCompare
11.8%21.1%14.7%
15.8%17.9%15.2%
10.1%17.7%
2.1%17.4%19.3%
3.0%15.8%13.9%
9.0%15.4%12.4%
27.6%14.6%10.5%
5.6%14.3%13.9%
12.9%13.9%13.5%
3.3%13.7%13.7%
10.8%13.6%10.7%
-0.9%13.5%12.2%
9.7%13.1%11.2%
3.2%12.0%10.1%
6.5%11.8%10.3%
2.2%11.7%9.9%
5.4%11.7%9.0%
4.0%11.6%11.6%
4.2%11.5%9.7%
3.9%11.4%8.8%
-3.7%11.2%11.8%
8.5%10.9%11.8%
3.5%10.7%8.6%
4.7%10.4%8.5%
1.9%9.3%9.7%
6.7%8.1%6.9%
6.8%7.6%6.9%
6.7%7.5%6.8%
6.6%7.4%6.7%
5.4%7.4%5.9%
6.5%7.3%6.8%
6.4%7.3%6.2%
-1.8%7.3%8.8%
5.5%7.1%6.0%
6.3%6.9%
6.5%6.9%6.3%
6.4%6.9%6.2%
3.1%6.4%5.0%
2.8%5.2%4.3%
-2.6%
PREVIEWTata India Pharma & Healthcare FundSectoral / Thematic · Direct · GrowthAnnualised return · from observed NAV
NAV39.6889
BenchmarkBSE Healthcare TRI
Expense ratio1.06%
AUM₹439 Cr
Fund managerRajat Srivastava
Volatility (3Y)13.26%
Maximum drawdown-16.81%
Risk labelVery High
Disclosed holdings37 securities
Portfolio disclosed99.1% by weight
Data date2 Sep 2026
SIP return (5Y, ₹10,000 a month)18.66% XIRR
Rolling 3Y · average / worst18.1% / -3.0%
Not yet available for this fund: Sharpe ratio, Sortino ratio.
What keeps it honest.
Research is only worth anything if the numbers can be traced. These four rules decide what appears and what is withheld.
Read the editorial policy →One snapshot per comparisonEvery metric in a view is pinned to a single dated snapshot, so no two columns are read from different days.
Every number is sourced and datedA figure you can see is a figure we can point at a publication for, with the date it belongs to.
Missing stays missingA value we cannot stand behind is left out and labelled, never quietly set to zero.
Its own legal benchmarkA fund is measured against the benchmark named in its scheme document, never a flattering stand-in.
The rest of the research plane
Compare fundsTwo to four funds side by side on one snapshot — returns, risk, cost, benchmark and overlap.MethodologyHow returns, benchmarks, overlap and concentration are computed, signed and verified.Data sourcesAMFI, SEBI disclosures, NSE and BSE, RBI and Nasdaq — each with its cadence and coverage.Editorial policyWhat OmniAsset will and will not claim, and how a factual error is corrected.
Research first. Add it to your portfolio only if you want to.
Looking something up never changes your holdings, and the search you type never leaves the browser.
Next: Compare fundsAndroid 8.0 and later · Free to track